Dopamine D4 receptor gene (DRD4) is associated with Novely Seeking (NS) and substance abuse: the sage continues% JM Lusher, CJ Chandler, DM Ball This article offers a review of research concerning the dopamine D4 receptor gene (DRD4) and its association with substance abuse and the personality trait Novelty Seeking (NS). There has been much controversy surrounding this association due to conflicting results and methodological differences between studies. It appears from the literature that there may be an association with DRD4 and NS amongst severe drug-dependent populations. Therefore, the DRD4 gene may not predispose individuals to addiction per se, but having the genetic variant may predispose substance abusers to a severe dependency.
This article discusses the notion that numerous candidate genes for psychiatric disorders may be regulated by the same transcription factors, and that polymorphisms in transcription factor genes might explain some phenotypes. The authors present data on thrombocyte monoamine oxidase (trbc MAO) and the transcription factor AP-2␤. Regardless of whether transcription factors, such as AP-2␤, regulate the expression of the number of monoamine neurons or a variety of monoaminergic genes, or both, the authors emphasize the role of transcription factors when explaining inter-individual differences in temperament and psychiatric vulnerability.
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Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake HE Ló pez-Valdé s, J García-Colunga
Nicotinic acetylcholine receptors (AChRs) are neurotransmitter-gated ion channels that play important roles in the nervous system. The present study examines effects of monoamine transporter inhibitors on the functioning of both rat neuronal ␣2␤4 and mouse muscle ␣1␤1␥␦ AChRs expressed in Xenopus laevis oocytes. For the two types of receptors the monoamineuptake inhibitors (norfluoxetine, clomipramine, indatraline, fluoxetine, imipramine, zimelidine, 6-nitroquipazine, trazodone) reduced the ionic current elicited by acetylcholine (ACh-current) albeit to different degrees. The tricyclic antidepressant imipramine inhibited reversibily and non-competitively the AChcurrent with a similar potency for both neuronal and muscle AChRs, probably by interacting externally on a non-conducting state of the AChR and by blocking the open ionic channel.
Short-and long-term effect of acetylcholinesterase inhibition on the expression and metabolism of the amyloid precursor protein M Racchi, M Sironi, A Caprera, G Kö nig, S Govoni
The authors have investigated the acute and chronic effect of metrifonate (MTF) and dichlorvos (DDVP), respectively the prodrug and active acetylcholinesterase inhibitor, on the secretory processing of the Amyloid Precursor Protein (APP) in SH-Sy5Y neuroblatoma cells. They have demonstrated that the acute treatment of SH-SY5Y cells with both compounds results in an increased secretion of the soluble fragment of APP (sAPP␣) into the conditioned media of cells, with a pattern correlated to the level of acetylcholinesterase inhibition. APP gene expression was unaffected by longterm AChE inhibition suggesting that increased shortterm sAPP␣ release does not elicit compensatory effects. The neurobiology of the cognitive interference is unknown. Previous brain imaging studies using the Stroop Color-Word (SCW) task indicate involvement of the anterior cingulate cortex (ACC) cognitive division. The authors employed in vivo proton magnetic resonance spectroscopy to examine interrelationships between regional brain N-Acetyl aspartate (NAA) levels and the SCW interference. The results show that brain chemistry depends on cognitive interference levels. These findings provide evidence of ACC involvement in cognitive interference suggesting a possibility of neuronal reorganization in the physiological mechanism of interference (most likely due to genetically predetermined control of the number of neurons, dendrites and receptors, and their function).
Cognitive interference is
Expression of corticotropin releasing hormone receptors type I and type II mRNA in normal individuals and suicide victims N Hiroi, ML Wong, J Licinio, C Parks, M Young, PW Gold, GP Chrousos, SR Bornstein
Corticotropin releasing hormone is a key regulator in the stress system and acts through its type I receptor on the HPA axis. Non-peptidergic CRH receptor antagonists are promising agents for stress-related diseases, including depression. This is the first comprehensive quantitative analysis of mRNA expression levels of the CRH receptor system in various human tissues. CRH receptors are widely expressed in human brain and peripheral tissues. In contrast to rodents, both CRH type I and type II receptors are stongly expressed in human pituitaries. In pituitaries of suicide victims there is a shift of the CRH-RI/CRH-RII ratio, suggesting that during severe stress the HPA axis may be activated through both receptor systems. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats V Butterweck, H Winterhoff, M Herkenham St John's wort is a medicinal plant used for centuries to treat depression. The basis for its efficacy has not been tested in animals in a way that would reveal how long-term administration in a therapeutic dosing regimen produces molecular neurochemical changes within brain circuits that process emotional informational content-specifically, chronic psychological stress. This article shows that St John's wort and imipramine, only when administered chronically, similarly altered gene expression in central components of the stress axis, notably in the hypothalamus, and they both countered the actions of stress on several key neurotransmitter systems controlling the HPA axis. This is the first study to show that St John's wort produces molecular changes in brain areas processing stressful information.
Association and linkage studies between bipolar affective disorder and the polymorphic CAG/CTG repeat loci ERDA1, SEF2-IB, MAB21L and KCNN3 IV Meira-Lima, J Zhao, P Sham, AC Pereira, JE Krieger, H Vallada Loci with CAG/CTG repeats are plausible candidates in the inheritance of bipolar affective disorder (BPAD) since evidence of anticipation has been reported in BPAD. In addition studies using the RED (repeat expansion detection) have shown association between BPAD and longer anonymous CAG/CTG repeats. The present study investigates the repeats in four loci: the ERDA-1 locus which accounts for most of the long CAG repeats detected by RED, the SEF2-1b locus which is placed in a region where positive linkage results have been reported and the loci MAB21L and KCNN3 as functional candidate genes. The extended transmission disequilibrium test (ETDT) and the linkage analysis in families with bipolar disorder showed negative results. Those data do not support the hypothesis that variation at the CAG/CTG repeat loci ERDA-1, MAB21L or KCNN3 influence susceptibility to BPAD.
Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium G Turecki, P Grof, E Grof, V D'Souza, L Lebuis, C Marineau, P Cavazzoni, A Duffy, C Bé tard, P Zvolský , C Brewer, TJ Hudson, GA Rouleau, M Alda Genetic mapping studies in bipolar disorder (BD) have been hampered by the unclear boundaries of the phenotypic spectrum, and possibly, by the complexity of the underlying genetic mechanisms, and heterogeneity. Among the suggested approaches to circumvent these problems, a pharmacogenetic strategy has been increasingly proposed. Several studies have indicated that patients with BD who respond well to lithium prophylaxis constitute a biologically distinct subgroup. In this study, the authors have conducted a complete genome scan using 378 markers spaced at an average follow-up of 12 years. Evidence for linkage was found with a locus on chromosome 15q14 (ACTC, lod score = 3.46, locus-specific P-value = 0.000014) and suggestive results were observed for another marker on chromosome 7q11.2 (D7S1816, lod score = 2.68, locus-specific P-value = 0.00011). This work suggests that loci on 15q14 and 7q11.2 may be implicated in the responsiveness to lithium in BD. B Lerer, F Macciardi, RH Segman, R Adolfsson, D Blackwood, S Blairy, J Del Favero, DG Dikeos, R Kaneva, R Lilli, I Massat, V Milanova, W Muir, M Noethen, L Oruc, T Petrova, GN Papadimitriou, M Rietschel, A Serretti, D Souery, S Van Gestel, C Van Broeckhoven, J Mendlewicz Genes that code for the multiple subtypes of serotonin receptors that are expressed in brain are strong candidates for a role in affective disorder. The authors examined a structural variant of the serotonin 2C (5-HT2C) receptor gene (HTR2C) that gives rise to a cysteine to serine substitution in the N terminal extracellular domain of the receptor protein (cys23ser). Five hundred and thirteen patients with recurrent, unipolar, major depression (MDD-R), 649 patients with bipolar (BP) affective disorder and 901 normal controls were drawn from nine European countries. Logistic regression analysis demonstrated that over and above this inter-population variability, there was a significant excess of HT2CR ser23 allele carriers in patients compared to normal controls that was demonstrable for both the MDD-R and BP patients. These findings support a possible role for genetically based structural variation in 5-HT2C receptors in the pathogenesis of major affective disorder.
Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity A Serretti, R Zanardi, D Rossini, C Cusin, R Lilli, E Smeraldi Converging evidence suggests that genetic predisposition plays an important role in antidepressant response. The authors previously reported that a functional polymorphism within the promoter region of the 5-HTT gene (5-HTTLPR) was related to the antidepressant response to fluvoxamine. The present study evidenced an effect of another polymorphism, the A218C tryptophan hydroxylase (TPH) gene variant. This effect was present only in subjects not taking potentiation therapy with pindolol and it was independent from the previously reported influence of the 5-HTTLPR polymorphism. If confirmed, these results may shed further light on the genetically determined component of the response to pharmacological treatments, thus helping the clinician to individualize each patient's therapy according to their genetic pattern.
Molecular Psychiatry
Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal S Akbarian, B Bates, R-J Liu, SL Skirboll, T Pejchal, V Coppola, LD Sun, G Fan, J Kucera, MA Wilson, L Tessarollo, BE Kosofsky, JR Taylor, M Bothwell, EJ Nestler, GK Aghajanianand, R Jaenisch Withdrawal reactions after chronic opiate exposure are thought to be due to disinhibition and dysregulation of brainstem noradrenergic neurons. Neurotrophin-3 (NT-3), a molecule of the nerve growth factor family is thought to modulate noradrenergic neuron function but conclusive evidence is still lacking. Here, the authors show that mice with a brain-specific deletion of the gene for NT-3 show an attenuated opiate withdrawal reaction. In addition, the noradrenergic neurons of mutant mice failed to show proper neurochemical adaptations upon chronic opiate exposure and also showed electrophysiological alterations. Surprisingly, the number of noradrenergic neurons was not altered in mice lacking NT-3 in brain. Taken together, these findings suggest that NT-3 modulates opiate withdrawal and noradrenergic neuron function but is not important for neuronal survival.
